Also known as: American Society for Clinical Oncology, ASCO
Merck and Moderna announced that their personalized mRNA cancer vaccine intismeran, combined with Keytruda, slowed melanoma recurrence in a late-stage trial. It is the first randomized Phase 3 trial to prove the benefit of neoantigen vaccines.
AstraZeneca is expanding in China with a $200m upfront COPD drug license from Sino Biopharmaceutical, a $1.5bn licensing deal for Dizal's Zegfrovy, and a $15bn manufacturing and R&D investment. The deals add revenue-generating assets to its respiratory and oncology portfolios.
AstraZeneca reported strong Q1 2026 results with 8% revenue growth and 12% operating profit growth, driven by its oncology portfolio and pipeline progress. The company also saw unusual options activity and maintained full-year guidance. Key oncology brands including Imfinzi and Enhertu showed double-digit growth.
A study of 450 mTNBC patients in community practices found high biomarker testing rates and encouraging outcomes across racial groups, with Hispanic patients showing the longest survival. However, Black women of West African ancestry face the highest TNBC incidence and greater neuropathy from paclitaxel, making docetaxel a potential alternative. Social determinants like neighborhood deprivation and allostatic load are also linked to TNBC risk.
AI identified rectal cancer patients who benefit from adding irinotecan to chemoradiotherapy, cutting recurrence and death risk. Separate research finds most online AI-cancer information is low quality and too complex for patients.
China's pharma industry hit record clinical drug trials and out-licensing deal values in 2025 and H1 2026, with NMPA approvals surging. The growth has drawn US Senate scrutiny and new bipartisan oversight legislation.
Four biomarkers—MMR, HER2, PD-L1, and Claudin 18.2—are now validated for advanced esophageal cancer, guiding immunotherapy and targeted treatment decisions. Checkpoint inhibitors show clear benefit in MSI-H and PD-L1-positive subgroups, with long-term survival observed. NCCN guidelines recommend broad testing to personalize therapy.
The FDA accepted Bristol Myers Squibb’s NDAs for iberdomide and mezigdomide, two CELMoD agents for relapsed/refractory multiple myeloma. Iberdomide has Priority Review and a PDUFA date of Aug. 17, 2026; mezigdomide’s is May 13, 2027. The filings are backed by Phase 3 data, including a 52% PFS risk reduction for mezigdomide.
ASCO 2026 data show CBM588 boosts immunotherapy in kidney cancer and a bispecific combo improves lymphoma. Early-day ICI infusion, mezigdomide T cell reinvigoration, and dostarlimab maintenance also advance cancer immunotherapy.
Daraxonrasib reduced death risk by 60% versus chemo in Phase 3 pancreatic cancer trial (median OS 13.2 vs 6.7 months). EMA began rolling review; zoldonrasib combo data presented at ESMO GI.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07676461 |
Oral, Fecal and Intratumoral Microbiome Atlas in Colombian Patients With Advanced Solid Tumors Receiving First-Line Immunotherapy |
RECRUITING | |
| NCT06964009 |
DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer |
RECRUITING | PHASE1 |
| NCT06907797 |
Tools for Reducing Inequity in Acute Leukemia (TRIAL): Beta Testing |
RECRUITING | NA |
| NCT06895473 |
Intrathecal Cytarabine, Methotrexate, and Hydrocortisone for the Prevention of High-Grade Chimeric Antigen Receptor T-Cell-Associated Neurotoxicity Syndrome |
RECRUITING | PHASE2 |
| NCT06795139 |
Pilot of a Trial Enrollment Diversity Dashboard |
COMPLETED | NA |
| NCT06582849 |
Enhanced Assistance During Radiotherapy for Unmet Essential Needs |
COMPLETED | NA |
| NCT06557512 |
Adjuvant Hypofractionated Stereotactic Radiosurgery for Intermediate-risk Meningioma |
RECRUITING | NA |
| NCT06469307 |
Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE) |
RECRUITING | NA |
| NCT06377852 |
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study |
RECRUITING | PHASE3 |
| NCT06089083 |
PROmOting Gynecologic Cancer Patients With Frailty to Achieve Functional Recovery |
RECRUITING |
